A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma

British Journal of Cancer

Volumn 92, Issue 3, 2005, Pages 445-448

  Arends, J J ^a   Sleeboom, H P ^b   Leys, M B L ^c   Ten Bokkel Huinink, D ^d   De Jong, R S ^e   Smit, J M ^f   Nortier, J W R ^a   Tesselaar, M E T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEYENBURG HOSPITAL   (Netherlands)

^c Medisch Centrum Rijnmond Zuid   (Netherlands)

^d DEPARTMENT OF SURGERY   (Netherlands)

^e MARTINI HOSPITAL   (Netherlands)

^f GELRE HOSPITALS   (Netherlands)

Author keywords

Gemcitabine; Pancreatic cancer; Phase II; Raltitrexed

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GEMCITABINE; RALTITREXED; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT GAIN; ADENOCARCINOMA; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; MIDDLE AGED; PANCREAS TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PANCREATIC NEOPLASMS; QUINAZOLINES; SURVIVAL RATE; THIOPHENES;

EID: 15244356686     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602368     Document Type: Article

References (32)

1. Aschele C, Sobrero A, Faderan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (Hct-8) sublines following exposure to 2 different clinically relevant dose schedules. Cancer Res 52: 1855-1864
2. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275
3. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Madiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, VanHoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
4. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
5. Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma - clinicopathologic analysis of 5-year survivors. Ann Surg 223: 273-279
6. Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, Sabatino M, Roviello F, Pinto E, Francini G, Giorgi G (2003a) Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. Eur J Cancer 39: 1547-1551
7. Correale P, Cerretani D, Petrioli R, Marsili S, Giorgi G, Francini G (2000) Gemcitabine and 5 fluorouracil in the treatment of patients with pancreas and colo-rectal carcinoma: a clinical and pharmacological study. ICACT 10th International Congress on Anti-Cancer Treatment January 31-February 3 2000, Paris, France, abs. no. 1-293
8. Correale P, Messinese S, Marsili S, Ceciarini F, Pozzessere D, Petrioli R, Sabatino M, Cerretani D, Pellegrini M, Di Palma T, Neri A, Calvanese A, Pinto E, Giorgi G, Francini G (2003b) A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer 89: 239-242
9. Cubiella J, Castells A, Fondevila C, Sans M, Sabater L, Navarro S, Fernandez-Cruz L (1999) Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am J Gastroenterol 94: 1271-1278
10. Cunningham D (1998) Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 77: 15-21
11. Feliu J, Mel R, Borrega P, Gomez LL, Escudero P, Dorta J, Castro J, Vazquez-Estevez SE, Bolanos M, Espinosa E, Baron MG (2002) Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann Oncol 13: 1756-1762
12. Ford HER, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, Calvert AH, Judson IR, Jackman AL (2002) Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 8: 103-109
13. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593-600
14. Haller DG (2003) Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 56: 16-23
15. Hansen R, Quebbeman E, Ritch P, Chitambar C, Anderson T (1988) Continuous 5-fluorouracil (5Fu) infusion in carcinoma of the pancreas - a Phase-II Study. Am J Med Sci 295: 91-93
16. Haycox A, Lombard M, Neoptolemos J, Walley T (1998) Review article: current treatment and optimal patient management in pancreatic cancer. Aliment Pharmacol Therap 12: 949-964
17. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H (1999) Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17: 585-592
18. Jaffee EM, Hruban RH, Canto M, Kern SE (2002) Focus on pancreas cancer. Cancer Cell 2: 25-28
19. Kornmann M, Link KH, Butzer U, Blatter J, Beger HG (1999) In vitro concentration response studies of gemcitabine as experimental base for regional chemotherapeutic studies. Eur J Cancer 35: S294
20. Kralidis E, Aebi S, Friess H, Buchler MW, Borner MM (2003) Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Ann Oncol 14: 574-579
21. Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim dH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K (2004) Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. Oncology 66: 32-37
22. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
23. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RCF (1994) Chemotherapy prolongs survival in inoperable pancreatic-carcinoma. Br J Surg 81: 882-885
24. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4-S66
25. Pazdur R, Meropol NJ, Casper ES, Fuchs C, Douglass HO, Vincent M, Abbruzzese JL (1995) Phase II trial of ZD1694 (Tomudex(TM)) in patients with advanced pancreatic cancer. Invest New Drugs 13: 355-358
26. Peters GJ, van der Wilt CL, Van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87: 227-253
27. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29
28. Ren Q, Kao V, Grem JL (1998) Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 4: 2811-2818
29. Shore S, Raraty MGT, Ghaneh P, Neoptolemos JP (2003) Chemotherapy for pancreatic cancer. Aliment Pharmacol Therap 18: 1049-1069
30. Tempero M, Plunkett W, van Haperen VR, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402-3408
31. Von Hoff DD (1996) Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team. Invest New Drugs 14: 265-270
32. Warshaw AL, Fernandezdelcastillo C (1992) Pancreatic-carcinoma. N Engl J Med 326: 455-465